NCT03860207View on ClinicalTrials.gov

Study of the Safety and Efficacy of Humanized 3F8 Bispecific Antibody (Hu3F8-BsAb) in Patients With Relapsed/Refractory Neuroblastoma, Osteosarcoma and Other Solid Tumor Cancers

PHASE1/PHASE2TerminatedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 22, 2019

Primary Completion Date

October 20, 2021

Study Completion Date

October 20, 2021

Conditions

NeuroblastomaOsteosarcomaOther Solid Tumor Cancers

Interventions

BIOLOGICAL

Humanized 3F8 Bispecific Antibody

Phase I Hu3F8-BsAb is given IV over \~1-3 hours on Days 1 and 8 for each cycle.Phase II Hu3F8-BsAb is given IV over \~1-3 hours on Days 1 and 8 for each cycle.

OTHER

Blood draw

In cycle 1, blood is drawn for PK studies.

Trial Locations (1)

10065

Memorial Sloan Kettering Cancer Center, New York